Special Session
DATE/TIME: May 30, 1:15 – 2:00 P.M.
PRESENTATION TITLE:
The Art of Getting Published in the Art of Oncology
LOCATION: S402A, JCO Central
ABSTRACT #: Lounge Program – No CE Credits
SPEAKER: Mikkael Sekeres, M.D.
Oral Presentations
DATE/TIME: May 30, 3:00 – 3:12 P.M.
PRESENTATION TITLE:
Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST)
LOCATION: S100bc
ABSTRACT #: 11500
CO-AUTHOR: Jonathan C. Trent, M.D., Ph.D.
DATE/TIME: May 30, 3:12 – 3:24 P.M.
PRESENTATION TITLE:
Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by KIT mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.
LOCATION: S100bc
ABSTRACT #: 11501
CO-AUTHOR: Jonathan C. Trent, M.D., Ph.D.
DATE/TIME: May 30, 3:48 – 4:00 P.M.
PRESENTATION TITLE:
Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
LOCATION: S100bc
ABSTRACT #: 11502
CO-AUTHOR: Jonathan C. Trent, M.D., Ph.D.
DATE/TIME: May 30, 4:42 – 4:48 P.M.
PRESENTATION TITLE:
MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
LOCATION: E451
ABSTRACT #: LBA9514
CO-AUTHOR: Jose Lutzky, M.D.
DATE/TIME: May 30, 5:00 – 5:06 P.M.
PRESENTATION TITLE:
A phase II study of neoadjuvant cemiplimab in hedgehog inhibitor (HHI)-naive basal cell carcinoma of the head and neck.
LOCATION: E451
ABSTRACT #: 9515
CO-AUTHOR: Leonel Hernandez Aya, M.D.
DATE/TIME: May 30, 5:24 – 5:36 P.M.
PRESENTATION TITLE:
Correlation of ten-year survival with cell-free DNA methylation of melanoma patients with asymptomatic brain metastases treated with nivolumab plus ipilimumab: The multicenter phase III NIBIT-M2 trial.
LOCATION: S100bc
ABSTRACT #: 2008
CO-AUTHOR: Michele Ceccarelli, Ph.D.
Poster Presentations
DATE/TIME: May 30, 9:00 A.M. – 12:00 P.M.
LOCATION: Hall A
SESSION TITLE: Care Delivery/Models of Care
PRESENTATION TITLE:
Evaluating AI decision support in a rapidly evolving therapeutic landscape: EGFR-mutant metastatic NSCLC.
ABSTRACT #: 1630 / Poster #: 548
FIRST AUTHOR: Chinmay Jani, MBBS
LAST AUTHOR: Gilberto Lopes, M.D.
CO-AUTHORS: Kyle Edwards, Estelemari Rodriguez
SESSION TITLE: Gastrointestinal Cancer — Colorectal and Anal
PRESENTATION TITLE:
Avatrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal malignancies (ACT-GI): A multicenter, U.S., randomized, double-blind, placebo-controlled clinical trial.
ABSTRACT #: 3580 / Poster #: 347
FIRST AUTHOR: Gerald A. Soff, M.D.
SESSION TITLE: Care Delivery/Models of Care
PRESENTATION TITLE:
Interpretable machine learning to identify health system levers for survival outcomes of patients with prostate cancer.
ABSTRACT #: 1595 / Poster #: 513
CO-AUTHOR: Brandon A. Mahal, M.D.
SESSION TITLE: Care Delivery/Models of Care
PRESENTATION TITLE:
Machine learning approach to identify country-specific drivers of global cancer outcomes.
ABSTRACT #: 1596 / Poster #: 514
CO-AUTHOR: Brandon A. Mahal, M.D.
SESSION TITLE: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary
PRESENTATION TITLE:
Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial.
ABSTRACT #: 4196 / Poster #: 179
CO-AUTHOR: Jashodeep Datta, M.D.
SESSION TITLE: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary
PRESENTATION TITLE:
Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).
ABSTRACT #: 4205 / Poster #: 188
CO-AUTHOR: Nkiruka Ezenwaijaku, M.D.
SESSION TITLE: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary
PRESENTATION TITLE:
A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti-CTLA-4 combined with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or with first-line durvalumab in advanced biliary tract cancer (BTC).
ABSTRACT #: TPS4255 / Poster #: 230a
CO-AUTHOR: Lynn G. Fuen, M.D.
DATE/TIME: May 30, 1:30 – 4:30 P.M.
LOCATION: Hall A
SESSION TITLE: Developmental Therapeutics — Immunotherapy
PRESENTATION TITLE:
A phase 1 trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms.
ABSTRACT #: TPS2700 / Poster #: Bd 472b 1630
FIRST AUTHOR: Chinmay Jani, M.D.
SESSION TITLE: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
PRESENTATION TITLE:
ETCTN 10302: A randomized phase I trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer.
ABSTRACT #: 3096 / Poster #: 233
CO-AUTHOR: Carmen Calfa, M.D.
SESSION TITLE: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
PRESENTATION TITLE:
Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.
ABSTRACT #: 3104 / Poster #: 241
CO-AUTHOR: Chukwuemeka Ikpeazu Sr., M.D.
SESSION TITLE: Symptom Science and Palliative Care
PRESENTATION TITLE:
BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia – A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
ABSTRACT #: 12080 / Poster #: 63
CO-AUTHOR: Agustin Pimentel, M.D.
SESSION TITLE: Developmental Therapeutics — Immunotherapy
PRESENTATION TITLE:
Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.
ABSTRACT #: 2616 / Poster #: 406
CO-AUTHOR: Leonel F. Hernandez-Aya, M.D.
SESSION TITLE: Developmental Therapeutics — Immunotherapy
PRESENTATION TITLE:
Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
ABSTRACT #: 2644 / Poster #: 434
CO-AUTHOR: Carmen Calfa, M.D.
SESSION TITLE: Developmental Therapeutics — Immunotherapy
PRESENTATION TITLE:
Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
ABSTRACT #: 2652 / Poster #: 442
CO-AUTHOR: Lawrence M. Negret, M.D.
SESSION TITLE: Developmental Therapeutics — Immunotherapy
PRESENTATION TITLE:
A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti-PD-1/PD-L1 antibody in participants with advanced non-small cell lung cancer (NSCLC).
ABSTRACT #: TPS2678 / Poster #: 461b
CO-AUTHOR: Estelemari Rodriguez, M.D.
SESSION TITLE: Head and Neck Cancer
PRESENTATION TITLE:
Efficacy and safety of pralsetinib in advanced or metastatic RET-altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.
ABSTRACT #: 6028 / Poster #: 485
CO-AUTHOR: Gilberto Lopes, M.D.
Oral Presentations
DATE/TIME: May 31, 5:06 – 5:12 P.M.
PRESENTATION TITLE:
Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.
LOCATION: S504
ABSTRACT #: 11516
CO-AUTHOR: Leonel Hernandez Aya, M.D.
DATE/TIME: May 31, 5:36 – 5:42 P.M.
PRESENTATION TITLE:
Association of NAB2-STAT6 distal fusion with risk level of metastatic disease and thoracic primary site.
LOCATION: S504
ABSTRACT #: 11519
FIRST AND PRESENTING AUTHOR: Keerthana Sureshkumar, B.S.
LAST AUTHOR: Gina D'Amato, M.D.
CO-AUTHORS: Mason Thornton, Eric Jung, Aryan Dalal, Kamal Amirneni, Emanuela Palmerini, Emily E. Jonczak, David Lombard, Francis Hornicek, Andrew Rosenberg, Jonathan C. Trent
DATE/TIME: May 31, 5:42 – 5:48 P.M.
PRESENTATION TITLE:
Efficacy of velzatinib (IDRX-42) in patients with advanced/metastatic GIST by line of therapy and circulating tumor DNA response in the phase 1/1b StrateGIST 1 trial.
LOCATION: S504
ABSTRACT #: 11520
CO-AUTHOR: Jonathan C. Trent, M.D., Ph.D.
Poster Presentations
DATE/TIME: May 31, 9:00 A.M. – 12:00 P.M.
LOCATION: Hall A
SESSION TITLE: Lung Cancer – Non-Small Cell Metastatic
PRESENTATION TITLE:
Disaggregated lung cancer mortality trends in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) patients by key sociodemographic features including sex, age, and smoking status.
ABSTRACT #: 8593 / Poster #: 383
CO-AUTHOR: Kyle Edwards
SESSION TITLE: Melanoma/Skin Cancers
PRESENTATION TITLE:
Transposable elements and homotypic niches as drivers of immune dynamics and resistance in melanoma epigenetic-based immunotherapy.
ABSTRACT #: 9531 / Poster #: 247
CO-AUTHOR: Michele Ceccarelli, Ph.D.
SESSION TITLE: Lung Cancer – Non-Small Cell Metastatic
PRESENTATION TITLE:
Lung cancer burden in AYAs: Global and U.S. trends.
ABSTRACT #: 8603 / Poster #: 393
CO-AUTHORS: Kyle Edwards, Estelemari Rodriguez, M.D., Gilberto Lopes, M.D., Chinmay Jani, M.D.
SESSION TITLE: Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
PRESENTATION TITLE:
Tarlatamab in small cell lung cancer with brain metastases: A real-world experience.
ABSTRACT #: 8108 / Poster #: 582
CO-AUTHORS: Chinmay Jani, M.D., Dan Morgenstern, M.D., Nelsy Zuniga, PharmD, Rakhi Modak, Kyle Edwards, Subul Malik, Kyle Rowley, Asad Rauf, Gilberto Lopes, M.D., Estelamari Rodriguez, M.D.
SESSION TITLE: Melanoma/Skin Cancers
PRESENTATION TITLE:
A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [212Pb]VMT01 melanocortin-1-receptor-targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.
ABSTRACT #: 9525 / Poster #: 241
CO-AUTHOR: Jose Lutzky, M.D.
SESSION TITLE: Melanoma/Skin Cancers
PRESENTATION TITLE:
Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance.
ABSTRACT #: 9568 / Poster #: 284
CO-AUTHORS: Eli Avisar, M.D., Jessica S. Crystal, M.D.
SESSION TITLE: Genitourinary Cancer – Kidney and Bladder
PRESENTATION TITLE:
Efficacy outcomes by patterns of progression in patients with advanced renal cell carcinoma from the phase 3 CLEAR trial.
ABSTRACT #: 4527 / Poster #: 6
CO-AUTHOR: Jaime R. Merchan, M.D.
SESSION TITLE: Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
PRESENTATION TITLE:
Tumor methylation subtypes as a predictor of clinical outcome to immunotherapy in pleural mesothelioma patients from the NIBIT-EPI-MESO study.
ABSTRACT #: 8052 / Poster #: 526
CO-AUTHORS: Teresa Maria Rosario Noviello, Michele Ceccarelli
Reception
DATE/TIME: May 31, 9:00 P.M.
TITLE:
Miami Nights, Sylvester's Reception During ASCO
LOCATION: Chicago Cultural Center, Preston Bradley Hall, 78 E. Washington Street, Chicago, IL 60602
RSVP:
Sylvester.org/MiamiNights
Oral Presentations
DATE/TIME: June 1, 9:48 – 10:00 A.M.
PRESENTATION TITLE:
Are We Breaking Barriers in Uveal Melanoma and Nonmelanoma Skin Cancers?
LOCATION: S100bc
ABSTRACT #: LBA9504, LBA9505, 9506, LBA9503
DISCUSSANT: Jose Lutzky, M.D.
DATE/TIME: June 1, 10:24 – 10:36 A.M.
PRESENTATION TITLE:
Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-Cell Therapy
LOCATION: S100bc
ABSTRACT #: 9508
CO-AUTHOR: Leonel Hernandez Aya, M.D.
DATE/TIME: June 1, 2:15 – 2:21 P.M.
PRESENTATION TITLE:
Tegavivint, a downstream Wnt/B-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
LOCATION: Hall D2
ABSTRACT #: 4015
CO-AUTHOR: Lynn G. Fuen, M.D.
Poster Presentations
DATE/TIME: June 1, 9:00 A.M. – 12:00 P.M.
LOCATION: Hall A
SESSION TITLE: Quality Care/Health Services Research
PRESENTATION TITLE:
Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations.
ABSTRACT #: 11026 / Poster #: 9
CO-AUTHORS: Warren Alperstein, M.D., Meghan McCormick, M.D.
SESSION TITLE: Gynecologic Cancer
PRESENTATION TITLE:
Racial disparities in endometrial cancer (EC) survival after molecular classification (MC).
ABSTRACT #: 5620 / Poster #: 286
CO-AUTHOR: Abdulrahman Sinno, M.D.
SESSION TITLE: Hematologic Malignancies – Plasma Cell Dyscrasia
PRESENTATION TITLE:
Artificial intelligence predicted natural killer cell fitness to guide daratumumab and transplant strategies in newly diagnosed multiple myeloma.
ABSTRACT #: 7520 / Poster #: 399
CO-AUTHORS: David G. Coffey, Dickran G. Kazandjian, Benjamin Diamond, Michael Durante, Brian Walker, James E. Hoffman, Abhishek Pandey, Rafat Abonour, Carl O. Landgren, M.D.
SESSION TITLE: Hematologic Malignancies – Plasma Cell Dyscrasia
PRESENTATION TITLE:
Association between survival outcomes in patients with multiple myeloma and treatment facility volume.
ABSTRACT #: 7529 / Poster #: 408
CO-AUTHORS: Carl O. Landgren, M.D., Gil Hevroni, Abhishek Pandey, Benjamin Diamond, M.D., David G. Coffey, M.D., James E. Hoffman, M.D., Dickran G. Kazandjian, M.D.
SESSION TITLE: Quality Care/Health Services Research
PRESENTATION TITLE:
Temporal trends in pregnancy-associated cancer mortality in the United States: A national analysis 2018–2023.
ABSTRACT #: 11029 / Poster #: 12
CO-AUTHOR: Ami Dave
SESSION TITLE: Medical Education and Professional Development
PRESENTATION TITLE:
Hematology-oncology bootcamp: Educational impact of an interactive, guideline-based "101" curriculum.
ABSTRACT #: 9035 / Poster #: 502
FIRST AND PRESENTING AUTHOR: Chinmay Jani, M.D.
CO-AUTHORS: Xena X. Zheng, M.D., Ali Al Sbihi, Akshee Batra, M.D., Thomas Plate, M.D., James E. Hoffman, M.D., Janaki N. Sharma, M.D.
SESSION TITLE: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
PRESENTATION TITLE:
Association of acute myeloid leukemia (AML) patient, disease, and molecular characteristics with a long-term (LT) response to olutasidenib.
ABSTRACT #: 6523 / Poster #: 316
FIRST AND PRESENTING AUTHOR: Justin M. Watts, M.D.
SESSION TITLE: Medical Education and Professional Development
PRESENTATION TITLE:
The hidden struggle? Mental health burden among oncology physicians globally.
ABSTRACT #: 9012 / Poster #: 479
FIRST AND PRESENTING AUTHOR: Coral Olazagasti, M.D.
SESSION TITLE: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
PRESENTATION TITLE:
Molecular landscape and outcomes of Black and White adults diagnosed with acute myeloid leukemia.
ABSTRACT #: 6519 / Poster #: 312
CO-AUTHOR: Mikkael Sekeres, M.D.
SESSION TITLE: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
PRESENTATION TITLE:
Molecular landscape and outcomes of Black and White adults diagnosed with acute myeloid leukemia.
ABSTRACT #: 6519 / Poster #: 312
CO-AUTHOR: Alvaro J. Alencar, M.D.
SESSION TITLE: Medical Education and Professional Development
PRESENTATION TITLE:
Preparedness of internal medicine residents for oncologic emergencies and end-of-life discussions in a community training environment
ABSTRACT #: 9017 / Poster #: 484
PRESENTING AUTHOR: Musa Kiyani, M.D., MBA, MPH
SESSION TITLE: Hematologic Malignancies – Plasma Cell Dyscrasia
PRESENTATION TITLE:
Enabling blood-based mass spectrometry MRD detection in multiple myeloma without archived serum samples.
ABSTRACT #: 7556 / Poster #: 435
PRESENTING AUTHOR: Daniel Jesus Groso, B.S.
CO-AUTHORS: Katie Thoren, Ph.D., Carl O. Landgren, M.D., David G. Coffey, M.D.
SESSION TITLE: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
PRESENTATION TITLE:
Multi-modal AI foundation models approach for diagnosis of myelodysplastic syndromes across whole bone marrow aspirate and biopsy slides.
ABSTRACT #: 6571 / Poster #: 364
CO-AUTHOR: Mikkael Sekeres, M.D.
SESSION TITLE: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
PRESENTATION TITLE:
Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME) + ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).
ABSTRACT #: TPS6604 / Poster #: 394b
CO-AUTHOR: Terrence J. Bradley, M.D.
SESSION TITLE: Hematologic Malignancies – Plasma Cell Dyscrasia
PRESENTATION TITLE:
Evaluating the impact of a statewide intervention on multiple myeloma bispecific T-cell engaging antibody (BsAb) therapy uptake in Florida (FL).
ABSTRACT #: 7532 / Poster #: 411
CO-AUTHOR: Andrew Kowalski, PharmD, BCOP
SESSION TITLE: Hematologic Malignancies – Plasma Cell Dyscrasia
PRESENTATION TITLE:
Immune effector cell-associated enterocolitis (IEC-EC) incidence and characterization in cilta-cel-treated patients with RRMM in CARTITUDE clinical studies.
ABSTRACT #: 7533 / Poster #: 412
CO-AUTHOR: Elizabeth Montgomery, M.D.
SESSION TITLE: Hematologic Malignancies – Plasma Cell Dyscrasia
PRESENTATION TITLE:
Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up.
ABSTRACT #: 7526 / Poster #: 405
CO-AUTHOR: James E. Hoffman, M.D.
DATE/TIME: June 1, 1:30 – 4:30 P.M.
LOCATION: Hall A
SESSION TITLE: Pediatric Oncology
PRESENTATION TITLE:
Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research (FOSTER) Consortium.
ABSTRACT #: 10032 / Poster #: 283
FIRST AND PRESENTING AUTHOR: Emanuela Palmerini, M.D., Ph.D.
SESSION TITLE: Pediatric Oncology
PRESENTATION TITLE:
Evaluating satisfactory testing versus transcript grade performance between childhood cancer survivors and healthy controls.
ABSTRACT #: 10045 / Poster #: 296
CO-AUTHORS: Bradley Gampel, M.D., Aditi Dhir, M.D., Christine F. Delgado, M.D.
SESSION TITLE: Sarcoma
PRESENTATION TITLE:
Integrating personalized ctDNA into clinical surveillance of soft tissue sarcoma: Performance, timing, and histologic insights.
ABSTRACT #: 11581 / Poster #: 371
CO-AUTHORS: Osvaldo Nunez Jr., Akshee Batra, Chinmay Jani, M.D., Palash Asawa, Alisette Naveda, Solange Sierra, APRN, Steven Bialick, D.O., Emanuela Palmerini, M.D., Gina Z. D'Amato, M.D., Jonathan C. Trent, M.D., Emily E. Jonczak, M.D.
SESSION TITLE: Prevention, Risk Reduction, and Genetics
PRESENTATION TITLE:
Predictors of EGFR-mutant primary lung adenocarcinoma.
ABSTRACT #: 10591 / Poster #: 552
FIRST/CO-AUTHOR: Lauren Kriger Groner
SESSION TITLE: Sarcoma
PRESENTATION TITLE:
Genomic characterization of conventional, dedifferentiated, and mesenchymal chondrosarcoma: A 550-patient multicenter analysis.
ABSTRACT #: 11528 / Poster #: 318
CO-AUTHORS: Emanuela Palmerini, M.D., Ph.D., Jonathan C. Trent, M.D.
SESSION TITLE: Sarcoma
PRESENTATION TITLE:
Distinct prognostic roles of IDH mutation and high-risk genomic alterations in patients with primary chondrosarcoma.
ABSTRACT #: 11550 / Poster #: 340
CO-AUTHORS: Kyra T. Berwitz, Allie L. Andryski, Roy Y. Miloh, Kristen K. Dean, Amrit Paudel, Osvaldo Nunez Jr., Emanuela Palmerini, M.D., Ph.D., H.T. Temple, M.D., Emily E. Jonczak, M.D., Gina Z. D'Amato, M.D., Brooke T. Crawford, Jonathan C. Trent, M.D.
SESSION TITLE: Breast Cancer – Metastatic
PRESENTATION TITLE:
Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
ABSTRACT #: 1108 / Poster #: 222
CO-AUTHORS: Lawrence M. Negret, M.D., Carmen Calfa, M.D.
SESSION TITLE: Central Nervous System Tumors
PRESENTATION TITLE:
Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
ABSTRACT #: 2028 / Poster #: 393
CO-AUTHOR: Akshee Batra
SESSION TITLE: Central Nervous System Tumors
PRESENTATION TITLE:
Characterization of contemporary practice patterns in the management of IDH-mutant glioma: A multidisciplinary multi-institutional survey.
ABSTRACT #: 2058 / Poster #: 423
CO-AUTHORS: Marina Kushnirsky, M.D., Benjamin J. Rich, M.D.
SESSION TITLE: Sarcoma
PRESENTATION TITLE:
Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
ABSTRACT #: TPS11589 / Poster #: 377b
CO-AUTHOR: Jonathan C. Trent, M.D.
SESSION TITLE: Breast Cancer – Local/Regional/Adjuvant
PRESENTATION TITLE:
A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer.
ABSTRACT #: 536 / Poster #: 21
CO-AUTHOR: Carmen Calfa, M.D.
SESSION TITLE: Breast Cancer – Local/Regional/Adjuvant
PRESENTATION TITLE:
National real-world adoption of 5-fraction breast radiotherapy in the United States (2020–2023).
ABSTRACT #: 590 / Poster #: 75
CO-AUTHOR: Manan Patel, M.S.
SESSION TITLE: Breast Cancer – Metastatic
PRESENTATION TITLE:
Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.
ABSTRACT #: 1024 / Poster #: 138
CO-AUTHOR: Priscila Barreto Coelho, M.D.
SESSION TITLE: Breast Cancer – Metastatic
PRESENTATION TITLE:
Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
ABSTRACT #: 1107 / Poster #: 221
CO-AUTHOR: Lawrence M. Negret, M.D.
Education Session
DATE/TIME: June 1, 3:24 – 3:36 P.M.
PRESENTATION TITLE:
Navigating a Successful Career in Academic Oncology: Strategies Throughout Your Many Chapters
LOCATION: E350
PRESENTER: Gilberto Lopes, M.D.
